GTG.AX - Genetic Technologies Limited
| Previous close | 0.0050 |
| Open | 0.0060 |
| Bid | 0.0050 x 0 |
| Ask | 0.0060 x 0 |
| Day's range | 0.0050 - 0.0060 |
| 52-week range | 0.0030 - 0.0120 |
| Volume | 3,746,288 |
| Avg. volume | 9,688,172 |
| Market cap | 36.069M |
| Beta (5Y monthly) | 1.12 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0020 |
| Earnings date | 01 Mar 2016 - 05 Mar 2016 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 0.25 |
- Simply Wall St.
Insider Buying: The Genetic Technologies Limited (ASX:GTG) Independent Non-Executive Chairman Just Bought 24% More Shares
Potential Genetic Technologies Limited (ASX:GTG) shareholders may wish to note that the Independent Non-Executive...
- GlobeNewswire
Genetic Technologies Announces Closing of $8.0 Million Public Offering
Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests, today announced the closing of its previously announced public offering of 3,500,000 American Depositary Shares (“ADSs”), each representing six hundred (600) of the Company’s ordinary shares, at an effective purchase price of $2.00 per ADS, and 500,000 pre-funded warrants, at an effective purchase price of $1.9999 per pre-funded warrant, for aggregate gross proceeds of approximately $8.0 million. The Company intends to use the net proceeds from this offering to support the introduction and distribution of our new products in the United States, for general product research and development, including the development of polygenic risk tests, and reimbursement studies with TGen in the United States, for implementation of our consumer initiated testing platform, preparation for potential COVID-19 testing, COVID-19 risk test for developing serious disease from contracting COVID-19, for working capital and new equipment purchases.
- GlobeNewswire
Genetic Technologies Announces Pricing of $8.0 Million Public Offering
Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests, today announced that it has priced a public offering of 4,000,000 American Depositary Shares (“ADSs”) (or ADS equivalents), each representing six hundred (600) of the Company’s ordinary shares, at an effective purchase price of $2.00 per ADS (or ADS equivalent). H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds from this offering are expected to be $8.0 million, before deducting the placement agent’s fees and other offering expenses payable by the Company.
- GlobeNewswire
Genetic Technologies Provides Operational Update - Successful Prototype Polygenic Risk Score for COVID-19 Created
To accompany that process, the Company will be working with its Consumer Initiated Testing (CIT) platform supplier to generate online product content to support sales activities in the USA. Leveraging Genetic Technologies’ core expertise in predictive risk modelling, the Company has also now completed analysis of the early, available genomic and phenotypic data from 1,500 COVID-19 patients.
- GlobeNewswire
Genetic Technologies - Accelerated development of new COVID-19 Polygenic Risk Test for Risk of Developing Life-Threatening Complications
Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) is to commence accelerating development of a polygenic risk score (PRS) test to predict an individual’s risk of developing life-threatening complications should they become infected with COVID-19. Dr George Muchnicki CEO said "GENE has secured a data set of over 1,500 patients who experienced COVID-19 and we intend on leveraging our core expertise in predictive risk modelling, to analyse the early, available genomic and phenotypic data from those COVID-19 patients with a view to developing a comprehensive predictive model to identify those patients most likely to require hospitalization, should they become infected with the COVID-19 virus."
- GlobeNewswire
Genetic Technologies Announces Closing of $1.44 Million Registered Direct Offering
Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests, today announced the closing of its previously announced registered direct offering of 722,502 American Depositary Shares (“ADSs”), each representing six hundred (600) of the Company’s ordinary shares, at a purchase price of $2.00 per ADS for gross proceeds of approximately $1.44 million. The Company intends to use the net proceeds from this offering to support the introduction and distribution of its new products in the United States, for general product research and development, including the development of polygenic risk tests with TGen in the United States, for implementation of its consumer initiated testing platform and preparation for Covid-19 testing as well as for working capital.
- GlobeNewswire
Genetic Technologies Announces $1.44 Million Registered Direct Offering
Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests, today announced that it has entered into definitive agreements with several institutional investors for the purchase and sale in a registered direct offering of 722,502 American Depositary Shares (“ADSs”), each representing six hundred (600) of the Company’s ordinary shares, at a purchase price of $2.00 per ADS. The gross proceeds to the Company from this offering are expected to be approximately $1.44 million, before deducting the placement agent’s fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from this offering to support the introduction and distribution of its new products in the United States, for general product research and development, including the development of polygenic risk tests with TGen in the United States, for implementation of its consumer initiated testing platform and preparation for Covid-19 testing as well as for working capital.
- GlobeNewswire
COVID-19 Testing Capacity at Genetic Technologies Accredited Laboratory
Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”) has developed a detailed implementation plan to enable a temporary transition of our genetic testing laboratory to a high-throughput COVID-19 testing laboratory, should it be required by Government agencies to assist with demand. Initial work to identify laboratory workflows, instrument modification, laboratory compliance for biologics and contaminated materials handling has commenced. This COVID-19 testing implementation plan has been developed as a result of the Company’s expectation of an increase in demand for COVID-19 testing and is not based on any existing agreement to provide COVID-19 testing.
- GlobeNewswire
Genetic Technologies Announces Closing of $1.8 Million Registered Direct Offering
MELBOURNE, Australia, April 06, 2020 -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests,.
- GlobeNewswire
Genetic Technologies Announces $1.8 Million Registered Direct Offering
Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests, today announced that it has entered into definitive agreements with several institutional investors for the purchase and sale in a registered direct offering of 1,028,574 American Depositary Shares (“ADSs”), each representing six hundred (600) of the Company’s ordinary shares, at a purchase price of $1.75 per ADS. The gross proceeds to the Company from this offering are expected to be approximately $1.8 million, before deducting the placement agent’s fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from this offering to support the introduction and distribution of its new products in the United States, for general product research and development, including the development of polygenic risk tests with TGen in the United States, for implementation of its consumer initiated testing platform, and for working capital.
- GlobeNewswire
Genetic Technologies Limited Announces Market Update on Sales, Early Test Results and Launch of Consumer Initiated Testing
Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”), provides the following update to the market. Breast Cancer and Colorectal Cancer tests commissioned, and sales commenced First Quarter 2020 with over 100 test kits distributed.
- GlobeNewswire
Genetic Technologies Limited Announces Receipt of Delisting Notification Letter from Nasdaq
The Letter indicates that Listing Rule 5815(d)(4)(B) does not permit an issuer that is deficient in stockholders’ equity to present a plan of compliance to the Nasdaq Staff if such issuer has failed to comply with that provision within one year of a Hearing Panel (the “Panel”) determination of compliance. On November 6, 2019, the Company received a letter from Nasdaq notifying the Company that it had regained compliance with the Equity Rule (the “Compliance Letter”).
- Simply Wall St.
Those Who Purchased Genetic Technologies (ASX:GTG) Shares Five Years Ago Have A 82% Loss To Show For It
While it may not be enough for some shareholders, we think it is good to see the Genetic Technologies Limited...
- GlobeNewswire
Genetic Technologies to provide Corporate & Strategic Update at 2020 Biotech Showcase
MELBOURNE, Australia, Jan. 13, 2020 -- Genetic Technologies (ASX: GTG; NASDAQ: GENE), a leader in the development of genetic risk assessment tests, recently announced the.
- GlobeNewswire
20 Medical centers across 8 US states set to offer Breast Cancer Test
Molecular diagnostics company Genetic Technologies Limited (ASX: GTG, NASDAQ: GENE) is pleased to advise that its third-generation breast cancer test (GeneType for Breast Cancer) is on track for commercial release in the Unites States (US) in Q1 2020. Genetic Technologies expects to take advantage of the growing confidence and interest in genomic testing, and its first to market status in the US market. GeneType for breast cancer (BC) is on track for release in the US in Q1 (2020) via a soft launch across 20 centres in 8 States, which demonstrates the strong support from practitioners for the introduction of the company’s third generation test incorporating mammography data.
- Simply Wall St.
Read This Before Selling Genetic Technologies Limited (ASX:GTG) Shares
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...
- GlobeNewswire
Genetic Technologies to Hold Investor Webinar and Q&A Session on December 18
MELBOURNE, Australia, Dec. 17, 2019 -- Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE, “Company”) is pleased to announce its interim-CEO, Dr. Jerzy Muchnicki, will share.
- GlobeNewswire
Genetype for Breast Cancer commissioned with sales to commence First Quarter 2020
Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE, “Company”) is pleased to announce the full commissioning of its Australian Laboratory for the provisioning of its generation 3 breast cancer test with sales to commence in Q1, 2020. Genetype for Breast Cancer is the world first Genomic test to accurately predict risk of disease by combining the information contained in your DNA with family history and mammography data to create a powerful new tool in the battle with breast cancer. Unlike BRCA gene testing which is used to detect the 1 in 400 women who carry this cancer associated genetic mutation, Genetype for Breast Cancer is relevant for the better management of 95% of all Breast cancers which are referred to as sporadic (or non-familial) and is ideally suited to be the first line test in a preventative medical genomic based health system.
- GlobeNewswire
Genetic Technologies Interview to Air on Bloomberg International on the RedChip Money Report
MELBOURNE, Australia, Nov. 15, 2019 -- Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE, “Company”), a diversified molecular diagnostics company, announced today an.
- GlobeNewswire
Genetic Technologies Provides Shareholder Update on Recent Achievements and Upcoming Milestones
Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE, “Company”), a diversified molecular diagnostics company, announced today an update to shareholders on recent achievements and upcoming milestones. As a result of the successful $4.5 million capital raise from existing shareholders, together with participation from domestic institutional and family office investors, the Company is now in compliance with Nasdaq listing requirements. The funds raised also position the Company to commence sales of its latest breast cancer and colorectal cancer risk assessment tests in both the U.S. and Australia.
